Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort - Ready, NE; Ott, PA; Hellmann, MD (J Thorac Oncol, 2020)
et al.